FDA says shortage of GLP-1 drug tirzepatide is over
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
HealthDay on MSN2d
FDA Says Shortage of GLP-1 Tirzepatide Is Over
The US FDA re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication ...
Everyday Health2d
FDA Says Shortages of GLP-1 Drugs Mounjaro and Zepbound Are Over
Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...
Hims & Hers: FDA Ruling May Close Compounded GLP-1 Drug 'Loophole', It Was Fun While It Lasted
Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...
There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
The National Law Review4d
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming ...
End to tirzepatide shortage has read on Hims GLP-1 trajectory, says Leerink
Leerink notes that the FDA today declared an end to the tirzepatide shortage, which “seemingly begins the process of bringing the compounded ...
Medical Xpress6d
FDA says shortage of GLP-1 tirzepatide is over
The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over. Tirzepatide includes blockbuster ...
Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst
Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help ...